Septodont and Acteon announce the signing of an agreement by which both Septodont and Acteon will become the shareholders of Inibsa

Septodont and Acteon have announced the signing of an agreement by which they will become the two shareholders of Inibsa, a global pharmaceutical group located in Barcelona, Spain. Subject to regulatory approvals, Septodont will acquire a controlling stake, alongside Acteon as a strong partner and non-controlling shareholder.

Inibsa has more than 75 years of experience providing products and services to healthcare professionals with an increasing focus on the dental industry. With a presence in more than 60 countries, this represents a unique opportunity for the company to develop its sales in dental products worldwide.

Septodont and Inibsa are focused on the needs of dental professionals and their patients. As two key companies in the dental health industry, they share the ambition to provide high quality products and solutions to customers worldwide. Acteon has developed a strong supply relationship with Inibsa. Acteon’s minority investment in Inibsa aims at developing further the existing partnership between the two companies.

This is an important acquisition for us that will provide compelling value creation and accelerated growth opportunities given the complementary nature of our assets and teams. We are thrilled to invest in Inibsa alongside Septodont. It will give Acteon the opportunity to strengthen its manufacturing position in the area of dental pharmaceutical products in Europe and Asia, added Markus Boehringer, CEO of Acteon.

Our shareholders were very supportive of this acquisition, which is the perfect complement of our current strategy, focusing on effective innovation, enhancing our customer service and strengthening operational capabilities. Today’s announcement marks the start of an exciting new chapter for Inibsa. In Septodont and Acteon, we have strong partners who are committed to strengthening and growing our business, said Eduard Lopez, General Manager of Inibsa.

The acquisition is subject to customary closing conditions and regulatory approvals. Completion is expected before the end of the year.